PSP Research LLC
CIK 2106939 · View on SEC EDGAR ↗
- Portfolio value
- $187.9M
- Positions
- 75
- As of
- June 30, 2026
#6,648 of 9,443 by 13F value · top 70.4%
Portfolio value QoQ: +32.9% 13F does not disclose cash
- Top 10 holdings weight
- 88.03%
- Top 25 holdings weight
- 92.09%
- Positions above 1%
- 2
- Effective number of positions
- 2.7
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 10.05% Est. buys $47,886,212 · sells $16,542,557
- New positions
- 11
- Increased
- 1
- Decreased
- 30
- Closed
- 15
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 99.7% · Options excluded: 0.0%
Sector breakdown
Healthcare
14.0%
Other/Unmapped
86.0%
Full portfolio 75 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| XBI XBI | $90,202,500 | 48.01% | 570,000 | $53,812,223 | Up ×1 | ||
| SGOV iShares 0-3 Month Treasury Bond ETF | $70,469,000 | 37.51% | 700,000 | $7,000 | |||
| RPRX Royalty Pharma plc - Class A Ordinary Shares | $616,770 | 0.33% | 11,000 | $89,100 | |||
| NRIX Nurix Therapeutics, Inc. - Common stock | $606,500 | 0.32% | 25,000 | $161,650 | Down ×2 | ||
| INCY Incyte Corporation - Common Stock | $600,808 | 0.32% | 5,300 | $101,972 | |||
| ARGX argenx SE - American Depositary Shares | $594,701 | 0.32% | 641 | $126,611 | |||
| IRON Disc Medicine, Inc. - Common Stock | $585,120 | 0.31% | 8,000 | $73,600 | |||
| RAPP Rapport Therapeutics, Inc. - Common Stock | $583,380 | 0.31% | 14,000 | $145,320 | |||
| RARE Ultragenyx Pharmaceutical Inc. - Common Stock | $567,630 | 0.30% | 17,000 | $104,635 | Down ×1 | ||
| TRVI Trevi Therapeutics, Inc. - Common Stock | $559,500 | 0.30% | 30,000 | $201,600 | |||
| GLUE Monte Rosa Therapeutics, Inc. - Common Stock | $556,600 | 0.30% | 23,000 | $96,000 | Down ×1 | ||
| TGTX TG Therapeutics, Inc. - Common Stock | $549,400 | 0.29% | 10,000 | $117,540 | Down ×2 | ||
| HALO Halozyme Therapeutics, Inc. - Common Stock | $547,890 | 0.29% | 7,000 | $29,170 | Down ×1 | ||
| IONS Ionis Pharmaceuticals, Inc. - Common Stock | $539,172 | 0.29% | 6,800 | $28,560 | |||
| PHVS Pharvaris N.V. - Ordinary Shares | $518,700 | 0.28% | 15,000 | $-46,300 | Down ×2 | ||
| ARQT Arcutis Biotherapeutics, Inc. - Common stock | $516,534 | 0.27% | 19,700 | $52,402 | |||
| AUPH Aurinia Pharmaceuticals Inc - Common Shares | $509,100 | 0.27% | 30,000 | $64,500 | |||
| NBIX Neurocrine Biosciences, Inc. - Common Stock | $505,605 | 0.27% | 3,000 | $-1,331 | Down ×1 | ||
| IMVT Immunovant, Inc. - Common Stock | $500,890 | 0.27% | 13,000 | $23,962 | Down ×2 | ||
| ACAD ACADIA Pharmaceuticals Inc. - Common Stock | $500,080 | 0.27% | 19,766 | $60,089 | |||
| PTCT PTC Therapeutics, Inc. - Common Stock | $489,420 | 0.26% | 6,000 | $80,640 | |||
| CLDX Celldex Therapeutics, Inc. - Common Stock | $483,730 | 0.26% | 13,000 | $71,370 | |||
| IMCR Immunocore Holdings plc - American Depositary Shares | $480,727 | 0.26% | 15,141 | $24,226 | |||
| DFTX Definium Therapeutics, Inc. - Common Shares | $470,400 | 0.25% | 10,000 | $-187,320 | Down ×1 | ||
| COGT Cogent Biosciences, Inc. - Common Stock | $464,400 | 0.25% | 12,000 | $2,520 | |||
| KYMR Kymera Therapeutics, Inc. - Common Stock | $458,680 | 0.24% | 4,000 | $-66,047 | Down ×2 | ||
| DYN Dyne Therapeutics, Inc. - Common Stock | $444,200 | 0.24% | 20,000 | $81,600 | |||
| ALNY Alnylam Pharmaceuticals, Inc. - Common Stock | $441,009 | 0.23% | 1,465 | $-43,716 | |||
| TARS Tarsus Pharmaceuticals, Inc. - Common Stock | $440,580 | 0.23% | 7,000 | $-50,470 | |||
| SNDX Syndax Pharmaceuticals, Inc. - Common Stock | $437,200 | 0.23% | 20,000 | $-30,000 | |||
| EXEL Exelixis, Inc. - Common Stock | $435,280 | 0.23% | 8,000 | $-77,170 | Down ×1 | ||
| CRNX Crinetics Pharmaceuticals, Inc. - Common Stock | $411,620 | 0.22% | 11,000 | $12,100 | |||
| NAMS NewAmsterdam Pharma Company N.V. - Ordinary Shares | $406,680 | 0.22% | 12,000 | $-73,470 | Down ×1 | ||
| Unknown issuer (CUSIP: K08588103) | $400,080 | 0.21% | 1,500 | Up ×1 | |||
| LQDA Liquidia Corporation - Common Stock | $398,650 | 0.21% | 5,000 | ||||
| STOK Stoke Therapeutics, Inc. - Common Stock | $392,640 | 0.21% | 12,000 | $1,920 | |||
| VKTX Viking Therapeutics, Inc. - Common Stock | $390,100 | 0.21% | 10,000 | $-98,000 | Down ×1 | ||
| IMNM Immunome, Inc. - Common Stock | $381,420 | 0.20% | 18,000 | $-55,980 | Down ×2 | ||
| PTGX Protagonist Therapeutics, Inc. - Common Stock | $367,740 | 0.20% | 3,000 | $51,540 | |||
| HRMY Harmony Biosciences Holdings, Inc. - Common Stock | $364,100 | 0.19% | 10,000 | $-35,967 | Down ×1 | ||
| ELVN Enliven Therapeutics, Inc. - Common Stock | $355,250 | 0.19% | 7,000 | $80,850 | |||
| SYRE Spyre Therapeutics, Inc. - Common Stock | $355,120 | 0.19% | 4,000 | $94,900 | Down ×2 | ||
| NTLA Intellia Therapeutics, Inc. - Common Stock | $338,400 | 0.18% | 20,000 | $-6,458 | Down ×1 | ||
| MDGL Madrigal Pharmaceuticals, Inc. - Common Stock | $322,170 | 0.17% | 600 | $8,088 | |||
| KNSA Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares | $319,750 | 0.17% | 5,000 | $-113,600 | Down ×2 | ||
| ALKS Alkermes plc - Ordinary Shares | $314,370 | 0.17% | 6,000 | $102,210 | |||
| TNGX Tango Therapeutics, Inc. - Common Stock | $312,600 | 0.17% | 10,000 | $11,352 | Down ×1 | ||
| ARDX Ardelyx, Inc. - Common Stock | $306,000 | 0.16% | 60,000 | $-173,200 | Down ×1 | ||
| VERA Vera Therapeutics, Inc. - Class A Common Stock | $300,370 | 0.16% | 7,000 | $-101,930 | Down ×1 | ||
| MIRM Mirum Pharmaceuticals, Inc. - common stock | $292,675 | 0.16% | 2,500 | $-169,225 | Down ×2 | ||
| ORKA Oruka Therapeutics, Inc. - Common Stock | $285,510 | 0.15% | 3,000 | $41,830 | Down ×1 | ||
| SUPN Supernus Pharmaceuticals, Inc. - Common Stock | $279,060 | 0.15% | 6,000 | $-31,080 | |||
| CRSP CRISPR Therapeutics AG - Common Shares | $272,700 | 0.15% | 5,000 | $-179,215 | Down ×2 | ||
| ZYME Zymeworks Inc. - Common Stock | $261,400 | 0.14% | 10,000 | $11,000 | |||
| KRYS Krystal Biotech, Inc. - Common Stock | $257,196 | 0.14% | 692 | Up ×1 | |||
| CMPS COMPASS Pathways Plc - American Depository Shares | $254,700 | 0.14% | 18,000 | $-137,930 | Down ×1 | ||
| XENE Xenon Pharmaceuticals Inc. - Common Shares | $253,512 | 0.13% | 4,200 | $9,282 | |||
| AXSM Axsome Therapeutics, Inc. - Common Stock | $244,770 | 0.13% | 1,000 | $-236,092 | Down ×1 | ||
| AVBP ArriVent BioPharma, Inc. - Common Stock | $244,604 | 0.13% | 7,041 | Up ×1 | |||
| DNTH Dianthus Therapeutics, Inc. - Common Stock | $243,700 | 0.13% | 2,500 | $-175,900 | Down ×2 | ||
| JAZZ Jazz Pharmaceuticals plc - Ordinary Shares | $233,982 | 0.12% | 971 | ||||
| KOD Kodiak Sciences Inc - Common Stock | $233,760 | 0.12% | 6,000 | $-147,440 | Down ×2 | ||
| RVMD Revolution Medicines, Inc. - Common Stock | $224,736 | 0.12% | 1,200 | ||||
| BBIO BridgeBio Pharma, Inc. - Common Stock | $223,440 | 0.12% | 3,000 | $-222,120 | Down ×2 | ||
| RYTM Rhythm Pharmaceuticals, Inc. - Common Stock | $222,060 | 0.12% | 2,000 | ||||
| DNLI Denali Therapeutics Inc. - Common Stock | $217,668 | 0.12% | 8,463 | ||||
| ARWR Arrowhead Pharmaceuticals, Inc. - Common Stock | $211,926 | 0.11% | 2,600 | ||||
| SRRK Scholar Rock Holding Corporation - Common Stock | $210,485 | 0.11% | 3,827 | Up ×1 | |||
| EWTX Edgewise Therapeutics, Inc. - Common Stock | $203,150 | 0.11% | 5,000 | $-1,600 | Down ×1 | ||
| AMLX Amylyx Pharmaceuticals, Inc. - Common Stock | $194,650 | 0.10% | 10,838 | $44,002 | |||
| CTMX CytomX Therapeutics, Inc. - Common Stock | $147,750 | 0.08% | 39,400 | Up ×1 | |||
| OCUL Ocular Therapeutix, Inc. - Common Stock | $147,300 | 0.08% | 15,000 | $20,250 | |||
| EYPT EyePoint, Inc. - Common Stock | $143,000 | 0.08% | 10,000 | $14,100 | |||
| ORIC Oric Pharmaceuticals, Inc. - Common Stock | $140,790 | 0.07% | 13,000 | $-23,920 | |||
| OLMA Olema Pharmaceuticals, Inc. - Common Stock | $125,100 | 0.07% | 10,000 | $-24,000 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| Unknown issuer (CUSIP: K08588103) | $400,080 | 1,500 | 0.21% |
| LQDA | $398,650 | 5,000 | 0.21% |
| KRYS | $257,196 | 692 | 0.14% |
| AVBP | $244,604 | 7,041 | 0.13% |
| JAZZ | $233,982 | 971 | 0.12% |
| RVMD | $224,736 | 1,200 | 0.12% |
| RYTM | $222,060 | 2,000 | 0.12% |
| DNLI | $217,668 | 8,463 | 0.12% |
| ARWR | $211,926 | 2,600 | 0.11% |
| SRRK | $210,485 | 3,827 | 0.11% |
| CTMX | $147,750 | 39,400 | 0.08% |
Top movers (QoQ)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| SERA | June 30, 2026 | 2,396,685 | $4,865,271 | 12.1% |
| TYRA | June 30, 2026 | 16,000 | $612,800 | -16.9% |
| TVTX | March 31, 2026 | 15,272 | $583,543 | 118.5% |
| ASND | June 30, 2026 | 2,500 | $571,825 | -4.0% |
| JAZZ | March 31, 2026 | 3,258 | $553,860 | 34.9% |
| CGON | March 31, 2026 | 13,293 | $551,925 | 16.0% |
| BLTE | March 31, 2026 | 3,443 | $550,742 | 3.5% |
| APLS | March 31, 2026 | 21,866 | $549,274 | No longer tracked |
| TERN | March 31, 2026 | 13,560 | $547,824 | No longer tracked |
| RVMD | March 31, 2026 | 6,872 | $547,355 | 124.2% |
| CNTA | March 31, 2026 | 21,879 | $547,194 | No longer tracked |
| CYTK | June 30, 2026 | 8,300 | $547,053 | -10.0% |
| MLYS | March 31, 2026 | 14,818 | $537,745 | 0.9% |
| ACLX | March 31, 2026 | 8,224 | $536,205 | No longer tracked |
| ROIV | March 31, 2026 | 24,621 | $534,276 | 33.8% |
| LQDA | March 31, 2026 | 15,485 | $534,078 | 95.7% |
| PVLA | March 31, 2026 | 5,084 | $532,142 | 20.8% |
| INSM | March 31, 2026 | 3,049 | $530,648 | -21.2% |
| NUVL | March 31, 2026 | 5,261 | $529,204 | No longer tracked |
| VRDN | March 31, 2026 | 16,967 | $528,013 | 25.1% |
| WVE | March 31, 2026 | 31,040 | $527,680 | -25.1% |
| MAZE | March 31, 2026 | 12,672 | $525,001 | -0.3% |
| DNLI | March 31, 2026 | 31,762 | $524,391 | 30.5% |
| BMRN | March 31, 2026 | 8,772 | $521,320 | 21.2% |
| BEAM | March 31, 2026 | 18,334 | $508,218 | 20.2% |
| AGIO | June 30, 2026 | 15,000 | $507,450 | -4.5% |
| RYTM | March 31, 2026 | 4,738 | $507,156 | 35.1% |
| PRAX | June 30, 2026 | 1,500 | $483,285 | 10.3% |
| UPB | March 31, 2026 | 17,634 | $478,763 | -21.9% |
| GPCR | March 31, 2026 | 6,719 | $467,306 | 11.4% |
| MNMD | March 31, 2026 | 34,841 | $466,521 | No longer tracked |
| INBX | June 30, 2026 | 6,927 | $465,702 | 4.4% |
| ARWR | March 31, 2026 | 6,689 | $444,083 | 41.5% |
| ALMS | March 31, 2026 | 43,769 | $427,185 | 16.0% |
| ERAS | June 30, 2026 | 17,327 | $280,351 | -1.5% |
| CELC | June 30, 2026 | 2,000 | $228,280 | -9.3% |
| KALV | June 30, 2026 | 10,795 | $217,303 | No longer tracked |
| LEGN | June 30, 2026 | 12,000 | $217,080 | -21.5% |
| APGE | June 30, 2026 | 2,500 | $210,425 | 1.5% |
| UTHR | June 30, 2026 | 350 | $207,543 | -1.5% |
| SMMT | June 30, 2026 | 10,223 | $193,828 | -11.0% |
| CMPX | June 30, 2026 | 30,000 | $158,700 | 13.5% |